Genzyme opts into Alnylam’s Thrombosis program
pharmafile | October 2, 2015 | News story | Medical Communications, Research and Development | Alnylam, Genzyme, Sanofi, haemophilia
Sanofi subsidiary Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialisation in territories outside of North America and Western Europe.
This marks the first product from Alnylam’s Genetic Medicines pipeline to which Genzyme has opted in since the formation of the companies’ global alliance in January 2014, and the third product opt-in overall.
Genzyme’s opt-in decision was based on encouraging clinical data from the Phase 1 trial of ALN-AT3, including positive interim data that was presented at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in June 2015.
David Meeker, president and CEO of Genzyme, says: “ALN-AT3 represents a unique and promising new approach for the potential treatment of haemophilia. We are excited to expand our clinical stage pipeline of treatments for patients with rare diseases, and to broaden our relationship with Alnylam.”
In January 2014, Alnylam and Genzyme formed an alliance to accelerate and expand the development and commercialization of RNAi therapeutics across the world. The alliance is structured as a multi-product geographic alliance in the field of rare diseases.
John Maraganore, CEO of Alnylam, says: “Our collaboration with Genzyme is a key part of our strategy to advance RNAi therapeutics to global markets. Genzyme’s proven track record in developing and commercialising therapies for rare diseases makes them an ideal partner to advance an innovative medicine for the treatment of haemophilia. Accordingly, we are very pleased that they have elected to opt into the ALN-AT3 program: the first product opt-in since formation of our landmark alliance.
“We believe that ALN-AT3 holds tremendous promise as a new investigational medicine for the management of hemostasis in hemophilia and rare bleeding disorders. We look forward to working with Genzyme to advance ALN-AT3 as a potential new treatment option for people with hemophilia around the world.”
Per the 2014 agreement, Alnylam will receive R&D funding for programs where Genzyme has elected to opt in for development and commercialisation.
Yasmita Kumar
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
